Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2022 - 2025)

ProQR Therapeutics' Long-Term Deferred Tax history spans 4 years, with the latest figure at $3.3 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 4.37% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 4.37% decrease, with the full-year FY2025 number at $3.3 million, down 4.37% from a year prior.
  • Long-Term Deferred Tax hit $3.3 million in Q4 2025 for ProQR Therapeutics, down from $3.5 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for PRQR hit a ceiling of $4.3 million in Q4 2023 and a floor of $3.3 million in Q4 2025.
  • Historically, Long-Term Deferred Tax has averaged $3.8 million across 4 years, with a median of $3.7 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: rose 7.13% in 2023 and later fell 18.73% in 2024.
  • Tracing PRQR's Long-Term Deferred Tax over 4 years: stood at $4.0 million in 2022, then increased by 7.13% to $4.3 million in 2023, then fell by 18.73% to $3.5 million in 2024, then dropped by 4.37% to $3.3 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for PRQR at $3.3 million in Q4 2025, $3.5 million in Q4 2024, and $4.3 million in Q4 2023.